

# Emma Hall

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/478231/publications.pdf>

Version: 2024-02-01

101  
papers

13,133  
citations

61984

43  
h-index

43889

91  
g-index

111  
all docs

111  
docs citations

111  
times ranked

14666  
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1697-1708.	27.0	1,796
2	A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer. <i>New England Journal of Medicine</i> , 2004, 350, 1081-1092.	27.0	1,694
3	Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. <i>Lancet Oncology</i> , The, 2011, 12, 127-136.	10.7	1,407
4	Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. <i>Lancet Oncology</i> , The, 2016, 17, 1047-1060.	10.7	941
5	Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Tj ETQq1 1,0,784314 rgBT /Ov	13.7	805
6	Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 1477-1488.	27.0	788
7	Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors. <i>BMJ: British Medical Journal</i> , 1994, 309, 911-918.	2.3	637
8	Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy. <i>New England Journal of Medicine</i> , 2012, 367, 895-903.	27.0	428
9	Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. <i>Lancet Oncology</i> , The, 2007, 8, 119-127.	10.7	404
10	Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. <i>Lancet Oncology</i> , The, 2012, 13, 43-54.	10.7	303
11	Clinical development of new drug-radiotherapy combinations. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 627-642.	27.6	230
12	Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. <i>Lancet Oncology</i> , The, 2012, 13, 65-77.	10.7	202
13	Quality of Life in the Intergroup Exemestane Study: A Randomized Trial of Exemestane Versus Continued Tamoxifen After 2 to 3 Years of Tamoxifen in Postmenopausal Women With Primary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 910-917.	1.6	180
14	Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. <i>Lancet</i> , The, 2009, 373, 1681-1692.	13.7	168
15	A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. <i>Radiotherapy and Oncology</i> , 2014, 111, 178-185.	0.6	128
16	Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. <i>Lancet Oncology</i> , The, 2015, 16, 1605-1616.	10.7	126
17	Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004). <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 261-269.	0.8	115
18	A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. <i>Nature Genetics</i> , 2014, 46, 891-894.	21.4	114

#	ARTICLE	IF	CITATIONS
19	Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011). <i>Trials</i> , 2011, 12, 78.	1.6	112
20	LIFE AND DEATH OF SPARE (SELECTIVE BLADDER PRESERVATION AGAINST RADICAL EXCISION): REFLECTIONS ON WHY THE SPARE TRIAL CLOSED. <i>BJU International</i> , 2010, 106, 753-755.	2.5	108
21	Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative. <i>European Journal of Cancer</i> , 2015, 51, 271-281.	2.8	108
22	Clinical and patient-reported outcomes of SPARE – a randomised feasibility study of selective bladder preservation versus radical cystectomy. <i>BJU International</i> , 2017, 120, 639-650.	2.5	105
23	Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer. <i>Radiotherapy and Oncology</i> , 2004, 73, 133-139.	0.6	99
24	Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. <i>Radiotherapy and Oncology</i> , 2016, 121, 431-439.	0.6	98
25	Randomized controlled trial of the effect of selenium supplementation on thyroid function in the elderly in the United Kingdom. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 370-378.	4.7	97
26	Impact of Selenium on Mood and Quality of Life: A Randomized, Controlled Trial. <i>Biological Psychiatry</i> , 2006, 59, 147-154.	1.3	91
27	R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology. <i>Frontiers in Oncology</i> , 2017, 7, 59.	2.8	90
28	Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. <i>British Journal of Cancer</i> , 2014, 110, 256-263.	6.4	85
29	Consensus Guidelines and Contouring Atlas for Pelvic Node Delineation in Prostate and Pelvic Node Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 874-883.	0.8	85
30	DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer. <i>BMC Cancer</i> , 2016, 16, 770.	2.6	83
31	Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capiwasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers. <i>Cancer Discovery</i> , 2020, 10, 1528-1543.	9.4	82
32	Non-randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema and tissue fibrosis after radiotherapy for early breast cancer. <i>Radiotherapy and Oncology</i> , 2004, 70, 217-224.	0.6	81
33	Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. <i>Radiology</i> , 2017, 283, 168-177.	7.3	81
34	Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. <i>Cancer Discovery</i> , 2021, 11, 2812-2827.	9.4	78
35	Dosimetric explanations of fatigue in head and neck radiotherapy: An analysis from the PARSPORT Phase III trial. <i>Radiotherapy and Oncology</i> , 2012, 104, 205-212.	0.6	73
36	Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. <i>EBioMedicine</i> , 2016, 10, 150-163.	6.1	69

#	ARTICLE	IF	CITATIONS
37	Human Epidermal Growth Factor Receptor 2 Status Correlates With Lymph Node Involvement in Patients With Estrogen Receptor (ER) –Negative, but With Grade in Those With ER-Positive Early-Stage Breast Cancer Suitable for Cytotoxic Chemotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 4423-4430.	1.6	66
38	Validation and Reliability Testing of the EORTC QLQ-NMIBC24 Questionnaire Module to Assess Patient-reported Outcomes in Non–Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2014, 66, 1148-1156.	1.9	66
39	Novel approaches to improve the therapeutic index of head and neck radiotherapy: An analysis of data from the PARSPORT randomised phase III trial. <i>Radiotherapy and Oncology</i> , 2012, 103, 82-87.	0.6	65
40	Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: Results at 4 years. <i>International Journal of Cancer</i> , 2005, 114, 94-100.	5.1	63
41	Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. <i>European Urology</i> , 2020, 77, 260-268.	1.9	58
42	Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial. <i>Journal of Cancer</i> , 2011, 2, 374-377.	2.5	55
43	Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapy. <i>Radiotherapy and Oncology</i> , 2005, 75, 334-341.	0.6	51
44	Double-blind, placebo-controlled, randomised phase II trial of IH636 grape seed proanthocyanidin extract (GSPE) in patients with radiation-induced breast induration. <i>Radiotherapy and Oncology</i> , 2006, 79, 45-51.	0.6	43
45	Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre Phase III trial comparing conventional radiotherapy and parotid-sparing IMRT for locally advanced head and neck cancer. <i>British Journal of Radiology</i> , 2009, 82, 585-594.	2.2	43
46	The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis. <i>European Urology</i> , 2020, 77, 344-351.	1.9	41
47	Time to define an international standard of postoperative care for resected upper urinary tract transitional cell carcinoma (TCC) – opening of the perioperative chemotherapy versus surveillance in upper tract urothelial cancer (POUT) Trial. <i>BJU International</i> , 2012, 110, 919-921.	2.5	37
48	Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6year results from the UK TACT trial (CRUK/01/001). <i>European Journal of Cancer</i> , 2014, 50, 2375-2389.	2.8	36
49	Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. <i>Cancer Discovery</i> , 2021, 11, 92-107.	9.4	36
50	Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES) – a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen. <i>Annals of Oncology</i> , 2010, 21, 498-505.	1.2	34
51	The Patient Deficit Model Overturned: a qualitative study of patients' perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer (SPARE, CRUK/07/011). <i>Trials</i> , 2012, 13, 228.	1.6	28
52	Two-Year and Lifetime Cost-Effectiveness of Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy for Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 683-689.	0.8	27
53	CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin – vs surgical management in low-risk non-muscle-invasive bladder cancer. <i>BJU International</i> , 2020, 125, 817-826.	2.5	27
54	Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker. <i>Radiology</i> , 2019, 293, 374-383.	7.3	25

#	ARTICLE	IF	CITATIONS
55	Alcohol and coronary heart disease reduction among British doctors: confounding or causality?. European Heart Journal, 1997, 18, 23-25.	2.2	24
56	Aromatase inhibitors as adjuvant therapies in patients with breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 2003, 86, 309-311.	2.5	21
57	Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. European Urology, 2021, 79, 307-315.	1.9	20
58	Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer, 2013, 109, 651-657.	6.4	19
59	Defining Bowel Dose Volume Constraints for Bladder Radiotherapy Treatment Planning. Clinical Oncology, 2015, 27, 22-29.	1.4	18
60	Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity. British Journal of Cancer, 2016, 114, 1165-1174.	6.4	17
61	Quality assuring "Plan of the day" selection in a multicentre adaptive bladder trial: Implementation of a pre-accrual IGRT guidance and assessment module. Clinical and Translational Radiation Oncology, 2019, 19, 27-32.	1.7	14
62	Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel inpatient dose escalation design in advanced cancer patients. Cancer Research, 2015, 75, CT323-CT323.	0.9	12
63	Results of a 2 x 2 Phase III Randomized Trial of Synchronous Chemo-radiotherapy (CRT) Compared to Radiotherapy (RT) Alone and Standard vs. Reduced High Volume RT in Muscle Invasive Bladder Cancer (MIBC) (BC2001 CRUK/01/004). International Journal of Radiation Oncology Biology Physics, 2010, 78, S2-S3.	0.8	10
64	The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). British Journal of Cancer, 2017, 116, 649-657.	6.4	9
65	Benefits and challenges of electronic data capture (EDC) systems versus paper case report forms. Trials, 2015, 16, .	1.6	8
66	Boxing Bladder Cancer with COX-2 specific Inhibition. Cancer Prevention Research, 2011, 4, 1534-1535.	1.5	6
67	Current attitudes of head and neck oncologists in the United Kingdom to induction chemotherapy for locally advanced head and neck cancer: A survey of centres participating in a national randomised controlled trial. Oral Oncology, 2014, 50, 141-146.	1.5	6
68	Prostate cancer and hypofractionation: reflections on recent randomised phase III clinical trial results. Translational Andrology and Urology, 2017, 6, 134-136.	1.4	5
69	HYBRID " Evaluating New Radiation Technology in Patients with Unmet Needs. Clinical Oncology, 2013, 25, 546-548.	1.4	4
70	Implementing electronic data capture (EDC) training for site staff. Trials, 2015, 16, .	1.6	4
71	EP-1566 MR-guided online adaptive radiotherapy: First experience in the UK. Radiotherapy and Oncology, 2019, 133, S845.	0.6	4
72	Letter in response to the Wedlake et al. paper "Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies". European Journal of Cancer, 2013, 49, 1783-1786.	2.8	3

#	ARTICLE	IF	CITATIONS
73	VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis. <i>British Journal of Cancer</i> , 2021, , .	6.4	3
74	Phase III trial of conformal radiotherapy following neoadjuvant hormone treatment in early prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 134-135.	0.8	2
75	First Toxicity Report of the BC2001 Trial: A Multicentre Phase III Randomised Trial of Radiotherapy with and without Synchronous Chemotherapy in Muscle Invasive Bladder Cancer ISCRTN No. 68324339, EUDRACT No. 2004-000164-26. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, S7.	0.8	2
76	Results of a Phase III Multi-centre Randomised Controlled Trial of Intensity Modulated (IMRT) vs Conventional Radiotherapy (RT) in Head&and Neck Cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). <i>Clinical Oncology</i> , 2010, 22, 899.	1.4	2
77	343 Translational phase I trial combining the AKT inhibitor AZD5363 (AZD) and PARP inhibitor Olaparib (Ola) in advanced cancer patients (pts). <i>European Journal of Cancer</i> , 2015, 51, S68.	2.8	2
78	Design considerations when transitioning from paper case report forms (CRFS) to electronic data capture (EDC). <i>Trials</i> , 2015, 16, .	1.6	2
79	Abstract CT322: DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer. , 2015, , .		2
80	A Road Map for Designing Phase I Clinical Trials of Radiotherapy&€Novel Agent Combinations. <i>Clinical Cancer Research</i> , 2022, 28, 3639-3651.	7.0	2
81	430 Cross-sectional study of Quality of Life (QL) 6 years after start of treatment in the UK Taxotere as Adjuvant Chemotherapy Trial (TACT; CRUK01/001). <i>European Journal of Cancer, Supplement</i> , 2010, 8, 184.	2.2	1
82	497 oral PHASE III PILOT STUDY OF DOSE ESCALATION USING CON-FORMAL RADIOTHERAPY IN PROSTATE CANCER: LONG TERM FOLLOW UP. <i>Radiotherapy and Oncology</i> , 2011, 99, S201.	0.6	1
83	Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups. <i>Trials</i> , 2011, 12, .	1.6	1
84	Using a Bayesian approach with reverse philosophy to design clinical trials in rare diseases. <i>Trials</i> , 2013, 14, .	1.6	1
85	2507 Prognostic factors in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). <i>European Journal of Cancer</i> , 2015, 51, S475-S476.	2.8	1
86	Remote training solutions for complex intervention trials. <i>Trials</i> , 2015, 16, .	1.6	1
87	Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancer. <i>Clinical and Translational Radiation Oncology</i> , 2018, 10, 1-6.	1.7	1
88	Abstract CT138: Translating preclinical observations to the clinic: Combination of the dual m-TORC1/2 inhibitor AZD2014 and paclitaxel in ovarian and lung cancer. , 2015, , .		1
89	A phase I trial of selective PI3K inhibitor taselisib (tas) plus palbociclib (palb) with and without endocrine therapy incorporating pharmacodynamic (PD) studies in patients (pts) with advanced cancers.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2573-2573.	1.6	1
90	Quantitative Estimates of the Effects of Concomitant Chemotherapy on Acute Dysphagia in Patients Receiving Radical Treatment for Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, S612.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Re: Marco Roscigno, Maurizio Brausi, Axel Heidenreich, et al. Lymphadenectomy at the Time of Nephroureterectomy for Upper Tract Urothelial Cancer. <i>Eur Urol</i> 2011;60:776-783. <i>European Urology</i> , 2012, 61, e16.	1.9	0
92	OC-0432: Evaluating the feasibility of sparing CNS structures to reduce acute fatigue from IMRT for head and neck cancer. <i>Radiotherapy and Oncology</i> , 2013, 106, S166.	0.6	0
93	OC-0154: IGRT for prostate cancer – results from the CHHiP IGRT phase II sub-study. <i>Radiotherapy and Oncology</i> , 2014, 111, S59.	0.6	0
94	2642 The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 (CRUK/01/004) trial. <i>European Journal of Cancer</i> , 2015, 51, S527-S528.	2.8	0
95	Dynamic prediction methods in the BC2001 clinical trial. <i>Trials</i> , 2015, 16, .	1.6	0
96	2579 Evaluation of clinical decision-making and the use of circulating tumor cells (CTCs) by physicians treating castration-resistant prostate cancer (CRPC). <i>European Journal of Cancer</i> , 2015, 51, S504.	2.8	0
97	OC-0340: Effect of dose and image guided radiotherapy (IGRT) on erectile potency (EP) in prostate radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 119, S156-S157.	0.6	0
98	Clinical management and research priorities for high-risk prostate cancer in the UK: Meeting report of a multidisciplinary panel in conjunction with the NCR1 Prostate Cancer Clinical Studies Localised Subgroup. <i>Journal of Clinical Urology</i> , 2016, 9, 369-379.	0.1	0
99	OC-0634 Implementation of plan of the day adaptive radiotherapy: Compliance to guidelines. <i>Radiotherapy and Oncology</i> , 2019, 133, S337-S338.	0.6	0
100	Reply to Wei Liu, Xiaoping Liu, Sheng Li's Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy + Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. <i>Eur Urol</i> 2020;77:260-268. <i>European Urology</i> , 2020, 77, e156-e157.	1.9	0
101	TAX-TORC: A phase I trial of vistusertib (AZD2014) in combination with weekly paclitaxel with integrated pharmacodynamic (PD) and molecular characterization (MC) studies. <i>Journal of Clinical Oncology</i> , 2017, 35, 2571-2571.	1.6	0